Caplin Point FY26 Annual Report: Revenue up 12.89 percent, PAT rises 20 percent

EBITDA margin expansionResults View source PDF Explain this filing

CAPLIPOINT · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.2%Reaction day

₹2720.20

prior close

₹2832.00

announcement price

In-mkt

timing

Nifty Smallcap 250market+1.0%+3.2% vs market

Pharmaceuticals peers, median of 172sector+0.3%+3.9% vs sector

On the reaction day the stock moved 3.2 pts more than Nifty Smallcap 250 and 3.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

+0.0

15m

-0.1

30m

+0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.2+1.0+3.2+0.3+3.9

Next day

+2.6+1.2+1.4+0.2+2.4

+4.0+1.2+2.7+0.8+3.2

+2.0+1.5+0.5+1.1+0.9

-0.3+1.0-1.2+0.8-1.1

+2.6+1.0+1.7+0.8+1.9

-5.4-2.0-3.5-1.0-4.4

15d

+4.2-0.5+4.8+0.8+3.5

-4.9-3.3-1.6-2.1-2.8

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Caplin Point Laboratories filed FY26 annual report for 35th AGM on Sept 25, 2026. Revenue from operations rose 12.89 percent to Rs 2,187 Cr; total revenue up 13.2 percent to Rs 2,303 Cr. EBITDA grew 17.9 percent to Rs 876 Cr, PAT up 20.08 percent to Rs 650 Cr, EPS at Rs 84.36. Zero-debt company with free cash reserves of Rs 1,471 Cr. R&D spend at 4.6 percent of revenue. Expansion via Mexico land acquisition and Guatemala facility planned.

Likely market impact

Strong all-round growth with zero debt and Rs 1,471 Cr cash reserves; EBITDA margins expanded; ongoing capacity expansion.